A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

Conditions

• Obesity
• Overweight
• Overweight and/or Obesity

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• PF-08653944 — DRUG
  By Subcutaneous Injection
• Placebo — OTHER
  By Subcutaneous Injection

Study Details

The purpose of this clinical study is to learn about the effects and safety of berobenatide (PF-08653944). This may help people with overweight or obesity lose weight. People in this study may also have type 2 diabetes. About 950 adults will be in this study. Berobenatide will be compared to a placebo. A placebo does not have any medicine in it but looks just like the medicine being studied. Berobenatide or placebo is given by a shot under the skin in the belly area. The objective of the study is to compare the experiences of people receiving berobenatide to those of the people who do not to assess if the study medicine is effective and safe. People will take part in this study for about 20 months. During this time, they will have about 15 study visits at the site. They will also have 2 study visits over the phone.

Key Dates

First listed

May 19, 2026

Start date

Jun 10, 2026

Status verified

Sep 2026

Primary completion

May 4, 2028

Completion

Jun 21, 2028

Study Design

Enrollment

954 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Treatment Arm 1
  Participants will receive PF-08653944 by Subcutaneous Injection.
• Experimental: Treatment Arm 2
  Participants will receive PF-08653944 by Subcutaneous Injection.
• Experimental: Treatment Arm 3
  Participants will receive PF-08653944 by Subcutaneous Injection.
• Experimental: Treatment Arm 4
  Participants will receive PF-08653944 by Subcutaneous Injection.
• Placebo Comparator: Placebo
  Participants will receive matching placebo by Subcutaneous Injection.

Primary Outcome Measure

Percent change from baseline in body weight [ Time Frame: Baseline, Week 72 ]

Central Contacts

• Pfizer CT.gov Call Center
  1-800-718-1021
  [email protected]

Locations (34)

Find similar trials in Canoga Park, CA

Related Studies

• Diabetes and Heart Disease Risk in Blacks
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Physical and Behavioral Traits of Overweight and Obese Adults
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
  Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia
• New Heart Imaging Techniques to Evaluate Possible Heart Disease
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland